Irritable Bowel Syndrome (IBS) Therapeutics – Pipeline Assessment and Market Forecasts to 2018

Aug. 31, 2011 - PRLog -- GlobalData estimates that the global IBS therapeutics market was valued at $655.8m in 2010, and is expected to grow at a compound annual growth rate (CAGR) of 11.7% in the forecast period to reach $1.6 billion by 2018. The high projected growth rate is primarily attributable to a strong pipeline and increasing disease awareness. Increases in the prevalence of the disease and the launch of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the IBS therapeutics market.

GlobalData analyzed the current competitive landscape for IBS drugs and found that the competition is
weak. Amitiza (lubiprostone) from Sucampo Pharmaceuticals, Inc. and Lotronex (alosetron) from GlaxoSmithKline are the two approved drugs present in the market, for the treatment of IBS-C and IBS-D
respectively, in the US, while Irribow (ramosetron) from Astellas Pharmaceuticals is available in Japan. Generics do not hold a major share in the market. GlobalData’s analysis of the entire competitive landscape of the branded products shows weak competition due to a lack of competing products for Amitiza and Lotronex in IBS-C and IBS-D respectively. The market is under-penetrated and has a huge potential for molecules with better safety and efficacy profiles. The market scenario will change after the launch of new disease-modifying therapies such as nerve growth factor (NGF) binders, transient receptor potential vanilloid (TRPV) antagonists, calcium channel blockers and so on.

GlobalData’s research indicates that the current treatment options are focused on offering symptomatic
relief from the various manifestations of IBS such as lower back pain, osteoarthritis pain, cancer pain, fibromyalgia and others. Therefore, the treatment is not focused on absolute cure of the disease, and is
thus only moderately efficacious. The IBS therapeutics market is divided into three classes based on the
different IBS subtypes (IBS can be classified on the basis of predominant bowel habit, as constipation predominant (IBS-C), diarrhea predominant (IBS-D), and an alternating form (IBS-M/IBS-A). This market
classification is due to the difference in marketed products approved with respect to the various subtypes.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

Considering the above facts, a huge unmet need exists for the IBS therapeutics market in all the classes
or subtypes which demand novel products offering improved efficacy and better safety profiles than the
existing products. Thus, there is ample opportunity for new entrants to enter into this market with product offerings which compete with the sub-type specific marketed drugs, offer overall improvement of symptoms and have better safety and efficacy profiles.

In summary, the IBS therapeutics market is expected to be a relatively open market for new entrants until 2018, with opportunities for value capture.

GlobalData, the industry analysis specialist, has released its new report, “Irritable Bowel Syndrome (IBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global IBS therapeutics market. The report identifies the key trends shaping and driving the global IBS therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report provides valuable insights on the
pipeline products within the global IBS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Irri...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.